23:26 , Jan 15, 2019 |  BC Extra  |  Company News

Sanofi expands multitargeting toolbox with Biomunex deal

Sanofi (Euronext:SAN; NASDAQ:SNY) has expanded its toolbox for developing multispecific modalities through a licensing deal with Biomunex Pharmaceuticals (Paris, France). The deal gives Sanofi access to Biomunex's Plug-and-Play BiXAb platform, which generates bi-specific and multispecific...
23:43 , Jan 14, 2019 |  BC Extra  |  Politics & Policy

House begins campaign to publicize and politicize drug pricing

Requests for pricing and cost information sent Monday by the House Oversight and Reform Committee to a dozen biopharma companies mark the start of what is certain to be a sustained campaign by House Democrats...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month's gains and losing $291.2 billion in aggregate value. Median losses...
18:17 , Jan 11, 2019 |  BC Week In Review  |  Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

By narrowing the focus of a 2015 immuno-oncology deal, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gains more freedom to play in its combinations sandbox as partner Sanofi (Euronext:SAN; NASDAQ:SNY) turns to other immuno-oncology agents in its pipeline....
18:16 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Schrödinger raises $85M in series E round

Computational physics company Schrödinger LLC (New York, N.Y.) raised $85 million on Jan. 4 in an untranched series E round co-led by existing investor The Bill and Melinda Gates Foundation Trust and the corporate venture...
17:30 , Jan 11, 2019 |  BC Week In Review  |  Company News

BioNTech to co-develop mRNA immunotherapy with Sanofi

BioNTech SE (Mainz, Germany) exercised an option under a 2015 deal to co-develop with Sanofi (Euronext:SAN; NASDAQ:SNY) an mRNA-based immunotherapy. Sanofi will make an €80 million ($91.5 million) equity investment in BioNTech. BioNTech said the...
01:04 , Jan 11, 2019 |  BioCentury  |  Finance

Exscientia looks inward

After spending six years building its artificial intelligence drug discovery platform and working with pharma partners, Exscientia Ltd. aims to use the bulk of the $26 million raised in a series B round to build...
00:11 , Jan 8, 2019 |  BC Extra  |  Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

By narrowing the focus of a 2015 immuno-oncology deal, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gains more freedom to play in its combinations sandbox as partner Sanofi (Euronext:SAN; NASDAQ:SNY) turns to other immuno-oncology agents in its pipeline....
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...